HUE050318T2 - Daganatos és fertõzõ betegségek kezelése céljából a mieloidokból nyert szupresszorsejtek megkülönböztetését kiváltó készítmények - Google Patents
Daganatos és fertõzõ betegségek kezelése céljából a mieloidokból nyert szupresszorsejtek megkülönböztetését kiváltó készítményekInfo
- Publication number
- HUE050318T2 HUE050318T2 HUE15794641A HUE15794641A HUE050318T2 HU E050318 T2 HUE050318 T2 HU E050318T2 HU E15794641 A HUE15794641 A HU E15794641A HU E15794641 A HUE15794641 A HU E15794641A HU E050318 T2 HUE050318 T2 HU E050318T2
- Authority
- HU
- Hungary
- Prior art keywords
- compositions
- infectious diseases
- treat cancer
- inducing differentiation
- derived suppressor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190370.8A EP3012271A1 (en) | 2014-10-24 | 2014-10-24 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE050318T2 true HUE050318T2 (hu) | 2020-11-30 |
Family
ID=51868772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15794641A HUE050318T2 (hu) | 2014-10-24 | 2015-10-21 | Daganatos és fertõzõ betegségek kezelése céljából a mieloidokból nyert szupresszorsejtek megkülönböztetését kiváltó készítmények |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170247464A1 (enExample) |
| EP (3) | EP3012271A1 (enExample) |
| JP (3) | JP6918279B2 (enExample) |
| CA (1) | CA2964203C (enExample) |
| DK (1) | DK3209691T3 (enExample) |
| ES (1) | ES2817074T3 (enExample) |
| HU (1) | HUE050318T2 (enExample) |
| PL (1) | PL3209691T3 (enExample) |
| WO (1) | WO2016063233A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| SG10202101909RA (en) | 2015-08-07 | 2021-04-29 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| PT3341015T (pt) | 2015-08-26 | 2021-10-12 | Univ Leland Stanford Junior | Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária |
| EP3365370A1 (en) * | 2015-10-21 | 2018-08-29 | OSE Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| EP4438626A3 (en) | 2016-04-14 | 2024-12-04 | OSE Immunotherapeutics | New anti-sirpa antibodies and their therapeutic applications |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3482772A4 (en) * | 2016-07-05 | 2020-03-04 | National University Corporation Kobe University | Antitumor agent |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| KR20240039236A (ko) | 2016-12-09 | 2024-03-26 | 알렉터 엘엘씨 | 항-sirp-알파 항체 및 그의 사용 방법 |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| US20190336516A1 (en) * | 2017-01-18 | 2019-11-07 | Nant Holdingsp Ip, Llc | Modulation of tumor cell susceptibility |
| JP7374769B2 (ja) * | 2017-02-15 | 2023-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｎｋ細胞を活性化するための組成物及び方法 |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| CA3091468A1 (en) | 2018-03-13 | 2019-09-19 | Ose Immunotherapeutics | Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies |
| MA52091A (fr) * | 2018-03-21 | 2021-01-27 | Alx Oncology Inc | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation |
| KR20210015872A (ko) | 2018-05-25 | 2021-02-10 | 알렉터 엘엘씨 | 항-sirpa 항체 및 그의 사용 방법 |
| JP7490554B2 (ja) | 2018-06-14 | 2024-05-27 | 株式会社明治 | 免疫チェックポイント阻害療法を促進するための組成物 |
| CN112543773B (zh) | 2018-07-11 | 2024-05-31 | 卡尔医学有限公司 | SIRPα-4-1BBL变体融合蛋白及其使用方法 |
| KR20210044221A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102904057B1 (ko) * | 2018-10-19 | 2025-12-24 | 오하이오 스테이트 이노베이션 파운데이션 | 나노-조작된 치료적 스텔스 세포 |
| BR112021024003A2 (pt) | 2019-05-31 | 2022-04-19 | Alx Oncology Inc | Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico |
| CN114206912B (zh) | 2019-06-07 | 2025-02-11 | Alx肿瘤生物技术公司 | 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂 |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| EP4157315A1 (en) | 2020-06-01 | 2023-04-05 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| US12098214B2 (en) | 2021-05-13 | 2024-09-24 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2023020459A1 (zh) | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| CN115896015B (zh) * | 2023-02-08 | 2023-09-29 | 上海诚益生物科技有限公司 | 一种髓系来源抑制性细胞的体外培养方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| ES2740823T5 (en) * | 2008-01-15 | 2025-12-26 | Univ Leland Stanford Junior | Methods for manipulating phagocytosis mediated by cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| JP6091891B2 (ja) | 2009-05-15 | 2017-03-08 | ユニバーシティ・ヘルス・ネットワーク | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| EP3682896A1 (en) * | 2011-04-28 | 2020-07-22 | University of Southern California | Human myeloid derived suppressor cell cancer markers |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| JP6460796B2 (ja) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｓｉｒｐ−アルファ試薬 |
| EA036963B1 (ru) * | 2013-02-06 | 2021-01-20 | Инхибркс, Инк. | Применение эпитопа cd47 для получения антитела к cd47 |
| SG11201607143UA (en) | 2014-03-11 | 2016-09-29 | Univ Leland Stanford Junior | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
-
2014
- 2014-10-24 EP EP14190370.8A patent/EP3012271A1/en not_active Withdrawn
-
2015
- 2015-10-21 EP EP15794641.9A patent/EP3209691B1/en not_active Revoked
- 2015-10-21 WO PCT/IB2015/058124 patent/WO2016063233A1/en not_active Ceased
- 2015-10-21 CA CA2964203A patent/CA2964203C/en active Active
- 2015-10-21 US US15/518,803 patent/US20170247464A1/en not_active Abandoned
- 2015-10-21 JP JP2017520986A patent/JP6918279B2/ja active Active
- 2015-10-21 ES ES15794641T patent/ES2817074T3/es active Active
- 2015-10-21 HU HUE15794641A patent/HUE050318T2/hu unknown
- 2015-10-21 DK DK15794641.9T patent/DK3209691T3/da active
- 2015-10-21 PL PL15794641T patent/PL3209691T3/pl unknown
- 2015-10-21 EP EP20177260.5A patent/EP3783027B1/en active Active
-
2021
- 2021-06-21 JP JP2021102148A patent/JP7253008B2/ja active Active
-
2022
- 2022-05-20 US US17/749,856 patent/US20220281993A1/en not_active Abandoned
-
2023
- 2023-03-24 JP JP2023047480A patent/JP2023078398A/ja active Pending
-
2024
- 2024-04-25 US US18/645,607 patent/US20240294659A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3209691T3 (pl) | 2020-11-16 |
| EP3783027B1 (en) | 2025-12-03 |
| CA2964203A1 (en) | 2016-04-28 |
| DK3209691T3 (da) | 2020-08-24 |
| WO2016063233A1 (en) | 2016-04-28 |
| US20170247464A1 (en) | 2017-08-31 |
| ES2817074T3 (es) | 2021-04-06 |
| EP3209691B1 (en) | 2020-07-15 |
| CA2964203C (en) | 2023-08-22 |
| EP3209691A1 (en) | 2017-08-30 |
| EP3783027A1 (en) | 2021-02-24 |
| EP3012271A1 (en) | 2016-04-27 |
| HK1243428A1 (en) | 2018-07-13 |
| JP2017538669A (ja) | 2017-12-28 |
| JP7253008B2 (ja) | 2023-04-05 |
| JP6918279B2 (ja) | 2021-08-11 |
| US20220281993A1 (en) | 2022-09-08 |
| JP2021155432A (ja) | 2021-10-07 |
| JP2023078398A (ja) | 2023-06-06 |
| US20240294659A1 (en) | 2024-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3209691T3 (pl) | Kompozycje do indukowania różnicowania komórek supresorowych pochodzących ze szpiku do leczenia chorób nowotworowych i zakaźnych | |
| PL3349783T3 (pl) | Kompozycje i sposoby do leczenia chorób | |
| IL259040B (en) | Use of toll-like receptor 8 agonists for cancer therapy | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| IL239453A0 (en) | Preparations and methods for treating cancer using bacteria | |
| IL239851B (en) | Methods and compositions for treating diseases that act to remove myelin | |
| IL257561A (en) | Methods for treating inflammatory diseases | |
| IL253118A0 (en) | Methods for treating inflammatory diseases | |
| PL3200815T3 (pl) | Sposoby i kompozycje do leczenia nowotworu | |
| IL247981A0 (en) | Preparations and methods related to the diagnosis of prostate cancer | |
| IL254842A0 (en) | Therapeutic preparations and methods for use in cancer treatment | |
| PT3157531T (pt) | Métodos e composições para estimulação do sistema enteroendócrino intestinal para tratamento de doenças ou condições relacionadas com o mesmo | |
| GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
| EP3131556A4 (en) | Methods and compositions for treatment of copd diseases | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| EP3221351A4 (en) | Methods and compositions for cancer treating conditions relating to over expressions of epha2 | |
| EP3155117A4 (en) | Alpha1-antitrypsin compositions and methods of treating autoimmune diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| ZA201509360B (en) | Compositions and methods for treatment of stroke | |
| ZA201506392B (en) | Compositions and methods including celecoxib and plumbagin relating to treatment of cancer | |
| IL252543A0 (en) | Compounds for the treatment of degenerative retinal tissues | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| PL3079684T3 (pl) | Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna | |
| ZA201805989B (en) | Compositions and methods of treatment of chronic infectious diseases | |
| GB201516303D0 (en) | Compositions and methods relating to the treatment of diseases |